Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
The final revisions to human research regulations arrived at the OMB, an indication that the first-ever overhaul of the so-called Common Rule will likely be released before President Barack Obama leaves office Jan. 20.
The White House Office of Management and Budget said it received the final rule (RIN: 0937-AA02) Jan. 4 and it is pending review. OMB review indicates a final stage before a new rule becomes public. If finalized, the Common Rule revisions would affect nearly 20 federal agencies, ranging from biomedical to aerospace, defense and energy research.
The Common Rule overhaul is such a big deal in research circles that stakeholders refer to the 2015 draft version as “the” proposed rule among the thousands that are moving through the federal government . But even if the new Common Rule comes out, Republicans are likely to resist implementing these changes. They criticized any move by the Obama administration to release eleventh-hour rules, and the House passed a bill Jan. 4 ( H.R. 21) that would allow Congress to repeal at once a slew of regulations issued in the last half of 2016.
“We’re still working on it,” Diane Gianelli, a spokeswoman for the Department of Health and Human Services, told Bloomberg BNA Jan. 5. But she couldn’t provide a release date. The HHS Office for Human Research Protections administers the regulations, but all the Common Rule agencies would have to sign off on the final version before it goes out.
Clinical trials of medical products regulated by the Food and Drug Administration are subject to a separate but similar set of human subject protection regulations (21 C.F.R. 56). The FDA plans to update its regulations so they line up with any Common Rule changes ( 09 LSLR, 10/30/15 ).
The OMB Office of Information and Regulatory Affairs has up to 90 days to review the final rule, so there is no guarantee a new Common Rule will move forward by Jan. 20. The OIRA/OMB review is the last required step before final rules can be published in the Federal Register, Gary Chadwick, a senior consultant with HRP Consulting Group, told Bloomberg BNA. Chadwick previously served as the associate director for human subject protections for both the OHRP and the FDA.
“Until the FR publication, the public is not able to access the text of the Final Rule,” he said. “Thus, the regulated community is still in the dark about what will change (scope and magnitude).”
“We can only wait to see if the Obama Administration will push this out in its final days. The change in Administration will certainly affect new rules as of January 20, but what the affect will be on this specific rule is unknown,” Chadwick said in a Jan. 5 e-mail. “By law, the Final Rule cannot become effective until at least 30 days after its publication.”
Lisa Nichols, director of research and regulatory reform for Council on Governmental Relations, thinks the final rule would be overturned once President-elect Donald Trump takes office. The proposed revisions to the Common Rule were among regulations that the House Freedom Caucus is looking to overturn in the first 100 days of the new administration, and Nichols noted Trump’s pick to run the OMB, Rep. Mick Mulvaney (R-S.C.), is a founding member of that conservative caucus.
“Perhaps they were concerned about REINS [ Regulations from the Executive in Need of Scrutiny Act of 2017] and thought this was the best approach,” Nichols said in a Jan. 5 e-mail to Bloomberg BNA, referring to legislation (H.R. 26) that would give Congress 70 legislative days to approve a major rule with an annual effect on the economy of $100 million or more.
“Perhaps they are thinking they can convince lawmakers and the next administration that the proposed changes are needed. I don’t see how they would be successful in that given that the research community and most other stakeholder groups strongly disagree,” Nichols said.
COGR, an association of research universities and affiliated medical centers and independent research institutes, expected the Common Rule to move forward based on previous statements from the HHS and National Institutes of Health, Nichols said.
“We feel this is an unfortunate move given the overwhelmingly negative comments to the proposed changes, including those from leading universities and academic medical centers,” Nichols said. She noted key groups, including the OHRP’s advisory committee and a National Academies panel, have called for withdrawing the proposed rule. “We believe due process would require the issuing of a revised Proposed Rule to allow further public comment prior to issuing a final rule.”
The Common Rule was designed to protect human subjects from undue harm in research, and the Obama administration has worked since its early days to modernize these regulations (45 C.F.R. 46), which have remained largely untouched since they went into effect in 1991. The revisions address major changes in research, including: biobanking; the explosion of genetic and genomic research; and the move from a one-site, one-investigator model to multisite clinical trials.
The 519-page proposed rule would:
To contact the reporter on this story: Jeannie Baumann in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at firstname.lastname@example.org
The OMB update is available by searching for the regulatory identification number 0937-AA02 on https://www.reginfo.gov.
The proposed new Common Rule is at https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)